Kolexia
Taieb Julien Gastro-entérologie
Taieb Julien
Gastro-entérologie
Hôpital Européen Georges Pompidou
Paris, France
744 Activités
1.9 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs colorectales Tumeurs du côlon Adénocarcinome Métastase tumorale Tumeurs du foie Tumeurs du pancréas Tumeurs du rectum Instabilité des microsatellites Récidive tumorale locale

Collaborateurs

Voir plus
Andre Thierry
Andre Thierry
Hôpital Saint-Antoine, Paris, France
Laurent-Puig Pierre
Laurent-Puig Pierre
Hôpital Européen Georges Pompidou, Paris, France
Pernot Simon
Pernot Simon
Institut Bergonié, Bordeaux, France
Bouche Olivier
Bouche Olivier
Hôpital Robert-Debré Reims, Reims, France

Industries

Voir plus
Servier
62 collaboration(s)
Dernière en 2023
Merck
32 collaboration(s)
Dernière en 2023
Pierre Fabre
30 collaboration(s)
Dernière en 2023
CanceroDigest
24 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
SEAMARK: A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600E-MUTANT, MSI H/DMMR METASTATIC COLORECTAL CANCER
Essai Clinique (Pfizer)   20 mars 2024
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer: AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER
Essai Clinique (Pfizer)   17 mars 2024
SCARCE: A Non-comparative Randomized 2:1 Phase II Study of Docetaxel, Cisplatin, and 5-fluorouracil in Combination or Not With Atezolizumab in Patients With Metastatic or Unresectable Locally Advanced Squamous Cell Anal Carcinoma
Essai Clinique (Roche)   08 mars 2024
CodeBreak300: A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
Essai Clinique (Amgen)   01 mars 2024
Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003): A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer Who Have Not Progressed Following First-line Induction (LYNK-003)
Essai Clinique (Merck & Co.)   01 mars 2024
Progression-Free Survival Analysis With a Graphical Estimand Approach in the Phase 2 SAMCO-PRODIGE 54 Trial-Reply.
JAMA oncology   29 février 2024
Triplet chemotherapy with or without bevacizumab as first line treatment for metastatic colorectal cancer: An AGEO multicenter real-world study.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver   24 février 2024
Non-metastatic colon cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatments, and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, AFEF, and SFR).
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver   20 février 2024
ANCHOR-CRC: Phase II, Open-label, Single Arm, Multicenter Study of Encorafenib, Binimetinib Plus Cetuximab in Subjects With Previously Untreated BRAF V600E -Mutant Metastatic Colorectal Cancer
Essai Clinique (Pierre Fabre)   31 janvier 2024
GEMOXIA-02: Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma: a Multicentric Single-arm Phase II Study
Essai Clinique (CHU Montpellier)   15 janvier 2024